Strategic targeting of the PI3K–NFκB axis in cisplatin-resistant NSCLC

Chemoresistance is a major therapeutic challenge to overcome in NSCLC, in order to improve the current survival rates of <15% at 5 years. We and others have shown increased PI3K signaling in NSCLC to be associated with a more aggressive disease, and a poorer prognosis. In this study, targeted inh...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Heavey, Susan, Godwin, Peter, Baird, Anne-Marie, Barr, Martin P, Umezawa, Kazuo, Cuffe, Sinéad, Finn, Stephen P, O’Byrne, Kenneth J, Gately, Kathy
Format: Artigo
Idioma:Inglês
Publicat: Landes Bioscience 2014
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4130730/
https://ncbi.nlm.nih.gov/pubmed/25025901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29841
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars